Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in uganda: Results from the first HIV vaccine trial in infants in Africa

Authors

Kenneth Kintu, Johns Hopkins University
Philip Andrew, Family Health International 360, Research Triangle Park, NC
Philippa Musoke, Johns Hopkins University
Paul Richardson, Johns Hopkins UniversityFollow
Brenda Asiimwe-Kateera, Johns Hopkins University
Teopista Nakyanzi, Johns Hopkins University
Lei Wang, Fred Hutchinson Cancer Research Center, Seattle, WA
Mary Glenn Fowler, Johns Hopkins University
Lynda Emel, Fred Hutchinson Cancer Research Center, Seattle, WA
San-San Ou, Fred Hutchinson Cancer Research Center, Seattle, WA
Lynn Baglyos, Sanofi Pasteur, Swiftwater, PA
Sanjay Gurunathan, Sanofi Pasteur, Swiftwater, PA
Sheryl Zwerski, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Jay Brooks Jackson, Johns Hopkins University
Laura Guay, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

5-1-2013

Journal

Journal of Acquired Immune Deficiency Syndromes

Volume

Volume 63, Issue 1

Inclusive Pages

1-8

APA Citation

Kintu, K., Andrew, P., Musoke, P., Richardson, P., Asiimwe-Kateera, B., Nakyanzi, T., Wang, L., Fowler, M.G., Emel, L., Ou, S.-S., Baglyos, L., Gurunathan, S., Zwerski, S., Jackson, J.B., Guay, L. (2013). Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in uganda: Results from the first HIV vaccine trial in infants in africa. Journal of Acquired Immune Deficiency Syndromes, 63(1), 1-8.

Peer Reviewed

1